Researching a name…

A US specialty pharma the market has somehow forgotten exists. Revenue +108% YoY. 50% gross margin. 36% operating margin. The kind of P&L large caps would envy, growing at small-cap speed.

Trading at ~7x earnings. Zero analyst coverage. Barely any liquidity.

Quiet for a reason. Quiet not forever.

The name is in the full report. Beautifully soon 👇

Read us. Join us. Sleep well. ✨